Swiss All Share Index
16.549,09
PKT
-18,32
PKT
-0,11
%
Werbung
Analysen zu Swiss All Share Index-Werten
Datum | Rating | Analyst | |
---|---|---|---|
28.04.05 | Swatch (I) Buy | Sarasin Research | |
27.04.05 | Richemont Verkaufen | Helaba Trust | |
27.04.05 | Roche Outperform | Goldman Sachs | |
28.04.05 | UBS Buy | Sarasin Research | |
27.04.05 | Richemont Outperform | Goldman Sachs | |
29.04.05 | Roche Sector Outperform | Vontobel | |
27.04.05 | Richemont Overweight | JP Morgan | |
26.04.05 | Geberit Market Outperform | Vontobel | |
26.04.05 | Nestlé Sector Outperform | Vontobel | |
27.04.05 | Roche Kaufen | Hamburger Sparkasse | |
26.04.05 | Richemont Outperform | Goldman Sachs | |
26.04.05 | Geberit Buy | Sarasin Research | |
26.04.05 | Nestlé In-Line | Goldman Sachs | |
27.04.05 | Roche Buy | Helvea | |
26.04.05 | Richemont Buy | Sarasin Research | |
26.04.05 | Nestlé Overweight | JP Morgan | |
27.04.05 | Richemont Accumulate | Helvea | |
26.04.05 | Nestlé Akkumulieren | Independent Research | |
02.05.05 | Richemont Kaufen | Hamburger Sparkasse | |
26.04.05 | Straumann Outperform | Goldman Sachs | |
26.04.05 | Kühne + Nagel International Neutral | Sarasin Research | |
26.04.05 | Swiss Life Buy | SRC Research | |
26.04.05 | Holcim Halten | Helaba Trust | |
26.04.05 | Novartis Kaufen | Hamburger Sparkasse | |
26.04.05 | Holcim Overweight | JP Morgan | |
25.04.05 | Straumann Sector Perform | Vontobel | |
22.04.05 | Novartis Hold | SEB | |
22.04.05 | Novartis Outperform | Goldman Sachs | |
22.04.05 | Novartis Overweight | Lehman Brothers | |
27.04.05 | Novartis Kaufen | NATIONAL-BANK | |
21.04.05 | Roche Outperform | Goldman Sachs | |
21.04.05 | Geberit Buy | Sarasin Research | |
21.04.05 | Novartis Akkumulieren | Independent Research | |
21.04.05 | Roche Sector Outperform | Vontobel | |
21.04.05 | Nestlé Neutral | Sarasin Research | |
21.04.05 | Kühne + Nagel International Neutral | Sarasin Research | |
25.04.05 | Lindt Neutral | Sarasin Research | |
22.04.05 | Sulzer Buy | Sarasin Research | |
21.04.05 | Novartis Neutral | Sarasin Research | |
21.04.05 | Novartis Buy | Merrill Lynch |